Arvinas Analyst Ratings
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Arvinas Holding Company (ARVN) Receives a Buy From Barclays
Truist Financial Maintains Arvinas(ARVN.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Cuts Target Price to $48
Stifel Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $63
Arvinas Holding Company (ARVN) Receives a Buy From Stifel Nicolaus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), Arvinas Holding Company (ARVN) and Jazz Pharmaceuticals (JAZZ)
Truist Financial Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
Truist Financial Maintains Arvinas(ARVN.US) With Buy Rating
HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
Buy Rating Affirmed for Arvinas Amidst Promising Clinical Trials and Strong Financial Outlook
The Latest Analyst Ratings For Arvinas
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $48 to $87
Arvinas Price Target Cut to $50.00/Share From $70.00 by Oppenheimer
Arvinas Analyst Ratings
Oppenheimer Adjusts Arvinas Price Target to $50 From $70, Maintains Outperform Rating
Barclays Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
Buy Rating Affirmed for Arvinas Holding Company Amid Promising Clinical Trial Developments